Avacta Group (LON:AVCT) Releases Earnings Results

Avacta Group (LON:AVCT) posted its quarterly earnings data on Tuesday. The biotechnology company reported GBX (9.27) earnings per share for the quarter, Digital Look Earnings reports. The firm had revenue of GBX 11 million during the quarter. Avacta Group had a negative net margin of 30,398.21% and a negative return on equity of 361.23%.

Avacta Group Stock Performance

Shares of AVCT stock opened at GBX 78.80 on Thursday. Avacta Group has a one year low of GBX 26 and a one year high of GBX 92. The company has a debt-to-equity ratio of 14,168.75, a quick ratio of 4.96 and a current ratio of 0.79. The company has a 50 day moving average price of GBX 73.19 and a 200 day moving average price of GBX 68.05. The firm has a market capitalization of £357.36 million, a price-to-earnings ratio of -4.49 and a beta of 1.12.

About Avacta Group

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics.
The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US.

Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).